Running hot in customers' hands: existing deployments are being used harder than they were sized for
The model's full reasoning — Q4 2023 call → NO我们根据要求,只使用提供的文本。问题问的是管理层是否描述了现有客户对产品/服务的使用强度在增加,超出预期。在文本中,寻找相关描述。 在文本中,关于Tyvaso DPI,提到“record revenue for Tyvaso on both royalty and collaboration manufacturing, along with record production on Tyvaso cartridges.” 以及“Tyvaso DPI royalty revenue for the fourth quarter was $21 million, which is 132% increase versus 2022, the result of continued growth in use of Tyvaso DPI for patients suffering from PAH and PH-ILD.” 这表示使用增长,但这是否是“现有客户使用更密集”还是“新客户增加”?文本说“continued growth in use”,但未明确区分新客户还是现有客户。另外,提到“we are making as much as we can around the clock”和“record production”,但这是供应侧。 关于Afrezza,提到“Afrezza net revenue grew $12 million, or 27% year-over-year. This is our largest jump in seven years and is the most we've seen driven by volume alone as opposed to price balance by historical standards.” 以及“underlying paid TRx growth of 25%”等。但这是否是现有客户使用更多?可能包括新处方,但未明确。 关键点:问题要求“existing customers”使用更密集,超出原始预期。文本中是否有这样的描述?例如,客户消耗更快,或使用率上升。在Tyvaso部分,提到“record production”和“record revenue”,但未明确说每个客户使用更多。在Afrezza部分,提到“volume alone”增长,但可能来自新患者。 另外,关于“we have never seen a better time”等,但具体到使用强度,没有明确说现有客户使用更多。 在文本中,有“we will make over 25 million doses and devices in 2024 and helped roughly 25,000 patients take a MannKind-produced product in 2023, the most in our history.” 这表示患者数量增加,但未说每个患者使用更多。 关于Tyvaso,提到“the result of continued growth in use of Tyvaso DPI for patients”可能包括新患者。 没有明确描述现有客户使用强度增加超出预期。管理层提到“record production”和“record revenue”,但未说这是由现有客户更密集使用驱动的。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| APYX | Apyx Medical Corporation | Q4 2023 | 2024-03-21 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| GEO | The GEO Group, Inc. | Q2 2016 | 2016-08-02 | B+ |
TJX · Q2 2021 → YESThe question is about whether management describes that the company's product, service, capacity, or offering — already deployed with existing customers — is being used more intensively than originall...
WES · Q3 2018 → YESThe question is about whether management describes that the company's product, service, capacity, or offering — already deployed with existing customers — is being used more intensively than originall...
BCE · Q2 2017 → YESThe question is about whether management describes that the company's product, service, capacity, or offering — already deployed with existing customers — is being used more intensively than originall...